Elobixibat is an IBAT inhibitor approved in Japan for the treatment of chronic constipation, the first IBAT inhibitor to be approved anywhere in the world. EA Pharma Co., Ltd., a company formed via a 2016 combination of Eisai’s GI business with Ajinomoto Pharmaceuticals and focused on the gastrointestinal disease space, is the exclusive licensee of elobixibat for the treatment of gastrointestinal disorders in Japan and other select countries in Asia (not including China) and co-markets elobixibat in Japan with Mochida Pharmaceutical Co., Ltd., and co-promotes elobixibat in Japan with Eisai, under the trade name GOOFICE®.
We own commercial rights to elobixibat in the United States, Europe, China and otherwise outside of the territories licensed to EA Pharma.
Bylvay™ (odevixibat) is approved for the treatment of pruritus in PFIC in the U.S. and for PFIC Europe. Elobixibat is approved for chronic constipation in Japan and Thailand. All other drugs and indications are currently investigational.